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Abstract
Background: The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618,
and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable
pancreatic cancer.
Methods: Patients with Stage II-IV locally advanced or metastatic pancreatic cancer were randomized (2:1) to either
230 mg of LY2603618/1000 mg/m2 gemcitabine combined or 1000 mg/m2 gemcitabine alone. OS was assessed
using both a Bayesian augment control model and traditional frequentist analysis for inference. Progression-free
survival (PFS), overall response rate (ORR), duration of response, pharmacokinetics (PK), and safety (Common Terminology
Criteria for Adverse Events [AEs] v 3.0) were also evaluated.
Results: Ninety-nine patients (n = 65, LY2603618/gemcitabine; n = 34, gemcitabine) were randomized (intent-to-treat
population). The median OS (months) was 7.8 (range, 0.3–18.9) with LY2603618/gemcitabine and 8.3 (range, 0.8-19.1+)
with gemcitabine. Similarly, in a Bayesian analysis, the study was not positive since the posterior probability
that LY2603618/gemcitabine was superior to gemcitabine in improving OS was 0.3, which did not exceed the
prespecified threshold of 0.8. No significant improvements in PFS, ORR, or duration of response were observed.
Drug-related treatment-emergent AEs in both arms included nausea, thrombocytopenia, fatigue, and neutropenia. The
severity of AEs with LY2603618/gemcitabine was comparable to gemcitabine. The LY2603618 exposure targets (AUC(0-∞)
≥21,000 ng hr/mL and Cmax ≥2000 ng/mL) predicted for maximum pharmacodynamic response were achieved after
230 mg of LY2603618.
Conclusions: LY2603618/gemcitabine was not superior to gemcitabine for the treatment of patients with pancreatic
cancer.
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Background
Pancreatic cancer is the fourth leading cause of cancer-
related deaths in the United States [1]. Current therapeutic
strategies for pancreatic cancer have a modest impact on
disease course and prognosis [2]. The 5-year survial rate
remains low (<5%) [3]. Until recently, gemcitabine was the
standard of care for patients with advanced/metastatic pan-
creatic cancer. FOLFIRINOX (oxaliplatin, irinotecan, leu-
covorin, and 5-FU) and gemcitabine plus nab-paclitaxel
(Abraxane®) are novel therapeutic regimens demonstrating
survival advantages in patients with advanced pancreatic
cancer [4–8]. Although these recent advances are promis-
ing, there is still a need for novel therapeutic targets to fur-
ther improve and sustain clinical response in pancreatic
cancer patients.
Checkpoint kinase 1 (CHK1) is a protein kinase in-
volved in the DNA damage response. Activation of
CHK1 initiates cell cycle arrest allowing for DNA repair
and replication. Inhibition of CHK1 allows cells to enter
mitosis without DNA repair, eventually leading to apop-
tosis [9]. Furthermore, inhibition of CHK1 sensitizes
tumor cells to DNA-damaging agents making CHK1 a
unique target for cancer therapy. Azorsa and colleagues
recently identified CHK1 as a therapeutic target for sen-
sitizing pancreatic cancer cells to gemcitabine therapy
using a synthetic lethal RNAi screening approach [10].
LY2603618, a selective CHK1 inhibitor, enhances the
activity of cytotoxic chemotherapy agents, including
gemcitabine, in in vitro and in vivo nonclinical efficacy
studies [11, 12]. Phase I of this Phase I/II study deter-
mined the recommended Phase II dose to be 230 mg
[13]. Phase II, as presented here, determined if the
overall survival (OS) in patients with Stage II-IV unre-
sectable pancreatic cancer who were administered
LY2603618 and gemcitabine exceeded the OS of pa-
tients treated with gemcitabine alone.
Methods
Study objectives
The primary objective of this Phase II study was to com-
pare OS with LY2603618/gemcitabine to gemcitabine
alone in patients with Stage II-IV unresectable pancre-
atic cancer. Secondary objectives included characterizing
the safety and toxicity profile of LY2603618/gemcitabine
and gemcitabine; estimating progression-free survival
(PFS), duration of response, and change in tumor size;
assessing response rates; evaluating the pharmacokinet-
ics (PK) of LY2603618; investigating biomarker re-
sponses; and performing an exploratory assessment of
Fridericia’s heart rate-corrected QT interval (QTcF).
Patients
Adult patients who had given informed consent had
adequate hematological, liver, and renal functions;
histological or cytological evidence of a diagnosis of Stage
II or III adenocarcinoma of the pancreas not amenable to
resection with curative intent or Stage IV disease; and an
Eastern Cooperative Oncology Group performance status
(ECOG PS) 0–2. Patients with previous radical surgery for
pancreatic cancer were eligible after progression was doc-
umented. Exclusion criteria included known hypersensi-
tivity to gemcitabine; females who were pregnant or
lactating; prior radiotherapy involving >25% of marrow-
producing area; and treatment with any non-approved
drug within 30 days of enrollment. Patients may have re-
ceived previous adjuvant treatment with gemcitabine.
Study design and treatment plan
Prior to enrollment, the study protocol, patient informed
consent, and any other written study documentation
were approved by an ethics committee. This trial was
conducted in accordance with the Declaration of
Helsinki and the Good Clinical Practice Guidelines of
the International Conference on Harmonization. Phase
II of this open-label, multicenter, randomized, 2-arm,
Phase I/II trial was conducted in patients with locally
advanced or metastatic pancreatic cancer. Patients were
randomized (2:1) to either LY2603618/gemcitabine or
gemcitabine. Gemcitabine (1000 mg/m2) was given as a
30-min infusion on days 1, 8, and 15 of a 28-day cycle.
LY2603618 (230 mg) was administered as a 1-h infusion
~24 h after administration of gemcitabine. Patients con-
tinued on treatment until disease progression, unaccept-
able toxicity, or patient unwillingness to participate.
Statistical analysis
The primary objective was a comparison of OS on
the intent-to-treat (ITT) population using a Bayesian
posterior probability for the superiority of the combin-
ation over gemcitabine. Ninety-nine patients were
planned, resulting in a frequentist design with ~60%
power (1-sided, 0.2 type I error, no interim analysis) to
detect a 2-month improvement in survival (7 months
gemcitabine vs. 9 months LY2603618/gemcitabine). The
Bayesian model [14, 15] incorporated historical gemcita-
bine data [16, 17] with prospective gemcitabine data to
compare survival between the treatment arms and in-
crease the power compared to the frequentist design.
LY2603618 and gemcitabine would be considered superior
to gemcitabine if the posterior probability of superiority
exceeded 0.8. Simulation resulted in estimated power of
0.76 and type I error rate of 0.15. In addition to the Bayes-
ian model, frequentist analysis of OS was also performed
as a sensitivity analysis. The definition of secondary effi-
cacy variables was consistent with standard conventions
per RECIST (v 1.1) [18].
Exploratory analyses included: change from baseline in
tumor size and carbohydrate antigen 19–9 (CA19-9)
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levels, and changes in QTcF from electrocardiograms
(ECG) obtained at baseline and after LY2603618 admin-
istration on days 2 and 16 during cycle one.
Safety
All patients who received at least one dose of study drug
were evaluated for safety and toxicity. AE severity was
graded using the Common Terminology Criteria for AEs
(CTCAE) v 3.0.
Pharmacokinetic/pharmacodynamic analysis
LY2603618 concentrations were quantified using a vali-
dated high-pressure liquid chromatography/mass spec-
trometry/mass spectrometry method. Whole blood
samples were collected following the LY2603618 infu-
sion on days 2 and 16 of cycle 1 before the start
(<10 min) of infusion; immediately prior to the end of
infusion (<5 min); and at 1, 3, and 24 h after the end of
infusion. LY2603618 PK parameters were computed
from the plasma concentration versus time data by
standard noncompartmental analyses (Phoenix WinNon-
lin version 6.3, Pharsight, A Certara Company®; Princeton,
NJ, USA). The PK parameters of maximum plasma con-
centration (Cmax) and area under the plasma concentra-
tion time-curve from time 0 to the time of the last
measurable plasma concentration (AUC[0-tlast]) or infinity
(AUC[0-∞]) on days 2 and 16 of cycle one were calculated,
as well as the terminal elimination half-life (t1/2), volume
of distribution at steady-state (Vss), systemic clearance
(CL), percentage of AUC[0-∞] extrapolated (%AUC[tlast-∞]),
and the intra- and intercycle accumulation ratios (RA).
Biomarker response
A nucleoside analog deoxyribonucleic acid (DNA) incorp-
oration assay method measured the amount of gemcita-
bine incorporated into genomic DNA [19]. A sample for
CA–19–9 analysis was collected at the start of each cycle.
Results
Patient disposition
Of the 107 enrolled patients, a total of 99 patients (n = 65,
LY2603618/gemcitabine; n = 34, gemcitabine alone) were
randomized and included in the ITT population. The first
patient was enrolled on 26 February 2009. Patient demo-
graphics and disease characteristics at baseline are sum-
marized in Table 1. The majority of the patient population
(mean age, 64 years) presented with Stage IV disease
(76.8%) and more than 90% had an ECOG PS 0–1 at study
entry (Table 1). The primary reasons for study discontinu-
ation in the LY2603618/gemcitabine arm and gemcitabine
alone arm, respectively, included: progressive disease
(70.8%; 61.8%), AE (12.3%; 17.6%), subject decision (4.6%;
14.7%), investigator decision (6.2%; 2.9%), death (4.6%;
2.9%), and protocol violation (1.5%; 0).
Clinical efficacy
The Bayesian model was applied to compare OS between
treatments. The posterior probability of superiority of
LY2603618/gemcitabine over gemcitabine alone was 0.33,
which did not exceed the pre-specified threshold of 0.8.
These findings were confirmed by the frequentist analysis.
The median OS was 7.8 months (range, 0.3–18.9 months)
for LY2603618/gemcitabine and 8.3 months (range, 0.8–
19.1+ months) for gemcitabine alone (Fig. 1a).
Overall, LY2603618/gemcitabine was not statistically
superior to gemcitabine alone when PFS, duration of re-
sponse, ORR, and clinical benefit rate were assessed
(Table 2). The median PFS was 3.5 months (range, 0–
15.9 months) for LY2603618/gemcitabine and 5.6 months
(range, 0–17.4 months) for gemcitabine (Table 2; Fig. 1b).
No complete response (CR) was observed with either
treatment. Although not statistically significant, a





(n = 65) (n = 34)
Age, years




Female 23 (35.4) 14 (41.2)
Male 42 (64.6) 20 (58.8)
Race, n (%)
White 62 (95.4) 32 (94.1)
Black or African American 2 (3.1) 2 (5.9)
American Indian or Alaska Native 1 (1.5) 0
BSA at baseline (m2)
Mean (SD) 1.8 (0.2) 1.8 (0.2)
Median 1.8 1.7
Range 1.3–2.5 1.4–2.5
Disease stage, n (%)
II 6 (9.2) 3 (8.8)
III 8 (12.3) 5 (14.7)
IV 50 (76.9) 26 (76.5)
Unknown 1 (1.5) 0
ECOG PS, n (%)
0 28 (43.1) 14 (41.2)
1 31 (47.7) 17 (50)
2 6 (9.2) 3 (8.8)
BSA body mass index; ECOG PS Eastern Cooperative Oncology Group
performance status; LY2603618/gemcitabine LY2603618 (230 mg flat dose)
combined with gemcitabine 1000 mg/m2; m2 meters squared; mg milligrams;
n number of patients; SD standard deviation
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Fig. 1 (See legend on next page.)
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numerically higher percentage of patients had a partial re-
sponse (PR) in the LY2603618/gemcitabine arm (21.5%;
95% confidence intervals [CI], 12.3–33.5) than in the gem-
citabine arm (8.8%; 95% CI, 1.9–23.7). No distinguishing
baseline characteristics were noted among patients with a
response. Due to the overlapping confidence intervals, the
clinical significance of the difference in response rates is
unknown. The clinical benefit rate was 55.4% (95% CI,
42.5–67.7) and 64.7% (95% CI, 46.5–80.3) in the
LY2603618/gemcitabine and gemcitabine arms, respect-
ively. No significant difference in the change in tumor size
(the sum of target lesions, per RECIST) from baseline to
8 weeks was observed between treatments (P = .6726).
Safety
The median number of cycles completed was 2.0 (range,
0–16 cycles) for LY2603618/gemcitabine and 2.5 (range,
0–18 cycles) for gemcitabine. As shown in Table 3, study
drug-related treatment-emergent AEs (TEAEs) were
comparable between LY2603618/gemcitabine (89.2%)
and gemcitabine (91.2%). The most frequently observed
TEAEs in both arms were nausea, thrombocytopenia, fa-
tigue, and neutropenia. Fewer patients experienced
anemia with LY2603618/gemcitabine (13.8%) than with
gemcitabine (26.5%). In contrast, a higher incidence of
vomiting, decreased appetite, and stomatitis was observed
for LY2603618/gemcitabine than for gemcitabine. For
each arm, neutropenia and thrombocytopenia were the
most common grade 3/4 TEAEs possibly related to treat-
ment, in addition to anemia, which was also common to
gemcitabine (Table 4). Serious adverse events (SAE) re-
lated to study treatment were reported among 13.8% and
23.5% of patients in the LY2603618/gemcitabine and gem-
citabine arms, respectively.
Fourteen patients (n = 8, LY2603618/gemcitabine; n = 6,
gemcitabine) discontinued the study due to AEs. Of the
eight patients who discontinued in the LY2603618/gemci-
tabine arm, four events (grade 4 cerebrovascular accident,
grade 1 left bundle branch block, grade 3 acute pulmonary
oedema, and grade 3 atrial fibrillation) were possibly re-
lated to treatment. Of the six patients who discontinued
in the gemcitabine arm, four possibly related events oc-
curred (grade 3 thrombotic microangiopathy, grade 4
(See figure on previous page.)
Fig. 1 a Overall survival. Kaplan Meier survival curves of patients treated with LY2603618/gemcitabine combination therapy compared with
historical gemcitabine studies. [1Jänne PA, Paz-Ares L, Oh Y, Eschbach C, Hirsh V, Enas N, Brail L, von Pawel J. Randomized, double-blind, phase II
trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung
cancer. J Thorac Oncol. 2014;9:126–31. 2Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmerman A, John W, Von
Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic
pancreatic cancer. Ann Oncol. 2005;16:1639–45.] b Progression-free survival. Kaplan Meier survival curves of patients treated with LY2603618/
gemcitabine compared with gemcitabine monotherapy




(n = 65) (n = 34)
Progression-free
survival, mos.
Median (range) 3.5 (0–15.9) 5.6 (0–17.4)
Duration of
response, mos.
Median (range) 3.5 (1.5–14.1) 6.0 (3.7–6.8)
Best Overall Response,
n (%; 95% CI)
CR 0 0
PR 14 (21.5%; 12.3–33.5) 3 (8.8%; 1.9–23.7)
SD 22 (33.8%; 22.6–46.6) 19 (55.9%; 37.9–72.8)
Clinical Benefit Rate,
n (%; 95% CI)
36 (55.4%; 42.5–67.7) 22 (64.7%; 46.5–80.3)
CI confidence interval; CR complete response; LY2603618/gemcitabine
LY2603618 (230 mg flat dose) combined with gemcitabine 1000 mg/m2; mos
months; n number of patients; PR partial response; SD stable disease
Table 3 Study drug-related treatment-emergent adverse events
in ≥10% of the safety population
Preferred Term, n (%) LY2603618/gemcitabine Gemcitabine
(n = 65) (n = 34)
Patients with ≥1 TEAE 58 (89.2) 31 (91.2)
Thrombocytopenia 21 (32.3) 14 (41.2)
Nausea 22 (33.8) 8 (23.5)
Fatigue 16 (24.6) 10 (29.4)
Neutropenia 14 (21.5) 9 (26.5)
Anemia 9 (13.8) 9 (26.5)
Vomiting 14 (21.5) 3 (8.8)
Decreased appetite 12 (18.5) 3 (8.8)
Diarrhea 11 (16.9) 3 (8.8)
Pyrexia 9 (13.8) 5 (14.7)
Asthenia 7 (10.8) 5 (14.7)
Constipation 9 (13.8) 3 (8.8)
Leukopenia 7 (10.8) 5 (14.7)
Stomatitis 10 (15.4) 1 (2.9)
Alopecia 6 (9.2) 4 (11.8)
Oedema peripheral 7 (10.8) 2 (5.9)
LY2603618/gemcitabine LY2603618 (230 mg flat dose) combined with
gemcitabine 1000 mg/m2; n number of patients; TEAE treatment-emergent
adverse events
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acute renal failure, grade 2 thrombocytopenia, and grade 3
hemolytic uraemic syndrome). Four deaths were reported
during the study; three due to disease progression and one
due to a non-related peripheral arterial ischemia event.
Pharmacokinetic/pharmacodynamic analyses
LY2603618 demonstrated consistent PK parameters after
single (day 2) and repeat administration (day 16) during
cycle 1 (Table 5). The LY2603618 plasma systemic ex-
posure targets (i.e., AUC(0-∞) ≥21,000 ng hr/mL and
Cmax ≥2000 ng/mL) that correlate with maximal phar-
macodynamic (PD) effect observed in nonclinical HT-29
xenograft models (data on file) were achieved on a mean
cohort basis after 230 mg of LY2603618 (Table 5). More
specifically, 87% and 73% of the individual PK profiles
on days 2 and 16 of cycle 1 were above the targets for
Cmax and AUC(0-∞), respectively.
For the PD analyses, dFdC was incorporated into
DNA following gemcitabine administration, with the
levels declining to almost baseline by the end of each
treatment cycle. The highest levels of dFdC incorpor-
ation were observed on days 8 and 15 across all doses.
The increases in the amount of dFdC incorporation did
not correspond to increasing doses of LY2603618.
Of the patients who had baseline CA19-9 levels > upper
limit of normal, a similar percentage of patients (65.4%
LY2603618/gemcitabine; 64% gemcitabine) experienced a
>50% reduction from baseline in CA19-9 levels.
QTcF assessment
In a time-point exploratory QTcF assessment, no clinic-
ally significant trends in ECG parameter changes were
reported. Five patients had a change in QTcF from base-
line between 30 and 60 milliseconds (msec); no patients
had a change in QTcF >60 msec.
Discussion
The current study was part of a Phase I/II study designed
to compare the OS of LY2603618/gemcitabine to gemcita-
bine alone. This study used a Bayesian augmented control
design to incorporate historical gemcitabine data, which
Table 4 Grade 3/4 study drug-related treatment-emergent adverse events in ≥5% of the safety population




Grade 3 Grade 4 Grade 3 Grade 4
Patients with ≥1 TEAE 25 (38.5) 6 (9.2) 19 (55.9) 3 (8.8)
Decreased hemoglobin 2 (3.1) 0 4 (11.8) 0
Decreased leukocytes 5 (7.7) 0 1 (2.9) 1 (2.9)
Decreased neutrophils/
Decreased platelets 7 (10.8) 0 3 (8.8) 1 (2.9)
Thrombotic microangiopathy 0 0 2 (5.9) 0
Fatigue 1 (1.5) 1 (1.5) 3 (8.8) 0
Dehydration 0 0 2 (5.9) 0
Hyponatremia 2 (3.1) 0 2 (5.9) 0
LY2603618/gemcitabine LY2603618 (230 mg flat dose) combined with gemcitabine 1000 mg/m2; n number of patients; TEAE treatment-emergent adverse events
Table 5 Summary of LY2603618 noncompartmental
pharmacokinetic parameter estimates
Parameter Geometric Mean (CV%) 230 mg LY2603618
Cycle 1
Day 2 Day 16
(n = 58) (n = 48)
Cmax (ng/mL) 3170 (50) 3410 (50)
tmax
a (h) 1.00 (0.88–1.38) 1.00 (0.88–1.83)
Cav,24 (ng/mL) 966 (68)
d 987 (60) e
AUC(0–24) (ng*h/mL) 23200 (68)
d 23700 (60) e
AUC(0-∞) (ng*h/mL) 29400 (84)
d 29100 (74) e
AUC(tlast-∞) (%) 14.3 (131)
d 12.0 (152) e
CL (L/h) 7.79 (84) d 7.87 (74) e
Vss (L) 104 (48)
d 95.1 (42) e
t1/2 (h) 9.67 (48)
d 8.86 (48) e
RA
b – 108 (32) f
RA
c – –
AUC(0 - ∞) area under the plasma concentration time-curve from time 0 to infin-
ity; AUC(0–24) area under the plasma concentration time-curve from time 0 to
24 h; AUC(tlast - ∞) fraction of AUC(0 - ∞) extrapolated from the time of the last
measurable plasma concentration (tlast) to infinity; Cav,24 average plasma con-
centration over 24 h calculated using AUC(0–24); CL systemic clearance; Cmax
maximum plasma concentration; CV% percent coefficient of variation; m2 me-
ters squared; mg milligrams; n number of pharmacokinetic observations; NC
not calculated; RA accumulation ratio; tmax time of maximum observed plasma
concentration; Vss volume of distribution at steady state following intravenous
(IV) administration; t1/2 elimination half-life
aMedian (range)
bIntracycle accumulation ratio [Cycle 1 Day 16 AUC(0 - ∞)/Cycle 1 Day 2 AUC(0 - ∞)]
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minimized the number of patients needed for the treat-
ment to be evaluated. Stage II or III patients not amenable
to resection with curative intent or Stage IV disease were
included in the current study to match the populations
used in the historical studies used as reference data. The
OS of LY2603618/gemcitabine was not superior to gemci-
tabine alone in patients with locally advanced or meta-
static pancreatic cancer by either the Bayesian or
frequentist approach. In addition, no significant differ-
ences between arms in any of the secondary endpoints
were observed.
The safety profiles were comparable between arms, in-
dicating that the addition of LY2603618 did not signifi-
cantly change the safety profile of gemcitabine. This is
consistent with the CHK1 inhibitor MK8776 [20], but in
contrast to the data reported with the CHK1 selective
inhibitors GDC-0425 and AZD7762 [21, 22]. In a Phase
1 study with AZD7762, unpredictable cardiac toxicity
was observed [21]. Although it was demonstrated safe
and feasible to administer GDC-0425 with gemcitabine,
the CHK1 inhibitor appeared to increase some of the
toxicities associated with gemcitabine [22].
A trend towards a lower LY2603618 systemic exposure
and more rapid CL associated with a larger interpatient
variability in Phase II (Table 5) compared to Phase I was
observed [13]. This is likely a result of the more limited
PK sampling schedule (sampling to only 24 h post dose)
used in the Phase II study (i.e., larger AUC(tlast-∞) (%)
values; Table 5), thereby limiting the capability of the
conventional PK analysis method to accurately quantify
the terminal elimination phase of LY2603618 and result-
ing in an underestimate of AUC(0-∞) and overestimate of
CL. In contrast, the LY2603618 PK profiles over the first
24 h from Phase II demonstrated a high degree of con-
cordance with the PK profiles from Phase I. The average
t1/2 following administration of 230 mg LY2603618 was
consistent with a t1/2 suitable for achieving and main-
taining the desired target human exposures while min-
imizing the intra- and intercycle accumulation (Table 5).
Gemcitabine did not appear to affect the PK of
LY2603618, as the PK parameters reported in this study
were similar to the PK parameters calculated after
LY2603618 monotherapy [23].
The study had inherent limitations that may have con-
tributed to the negative clinical outcome observed. In
addition, due to the lack of a clinically-validated PD
marker to quantify direct CHK1 inhibition by LY2603618,
the magnitude and duration of CHK1 target inhibition at
230 mg is neither known nor has it been correlated to
clinical responses. Therefore, it is possible the PK surro-
gate targets (i.e., AUC(0-∞) ≥21,000 ng•hr/mL and Cmax
≥2000 ng/mL) derived from nonclinical xenograft models
for maximal PD response were not appropriate thresholds
to predict clinical responses in humans. In addition,
inclusion of only patients with Stage IV disease may have
yielded a more favorable clinical outcome.
One Phase III randomized trial comparing gemcitabine
with FOLFIRINOX reported statistically significant im-
provements in OS (hazard ratio [HR] 0.57, P < .0001),
PFS (HR 0.47, P < .0001), and ORR (P = .0001) in chemo-
naïve patients with ECOG PS 0 and 1 [5]. Despite the clin-
cial efficacy observed with FOLFIRINOX, this treatment
was associated with more frequent and more severe tox-
icity [5]. As a result, only patients with an adequate PS are
typically eligible for FOLFIRINOX treatment. Recent
meta-analyses have reported that patients with poorer per-
formance had less OS benefit from combined therapies
for metastatic pancreatic cancer [24, 25]. Since FOLFIRI-
NOX emerged as a treatment option during the conduct
of this study, there was concern that a greater proportion
of patients with low PS status who were not eligible for
FOLFIRINOX would be included. However, only 9.2% and
8.8% of patients on the experimental arm and control
arm, respectively, were PS 2 and so this consideration was
unlikely to have affected the outcome.
The Metastatic Pancreatic Adenocarcinoma Clinical
Trial (MPACT) demonstrated improved clinical efficacy
with gemcitabine/nab-paclitaxel than gemcitabine (me-
dian OS, 8.5 months vs. 6.7 months, respectively); how-
ever, fatigue, neuropathy, and neutropenia were more
common among patients receiving combination therapy
than monotherapy [4, 8]. Interestingly, the overall inci-
dence of grade III/IV study drug-related TEAEs in the
current study was not increased in the LY2603618/gem-
citabine arm compared with the gemcitabine arm, except
for the incidence of grade 3 leukocytes and platelets,
which was higher in the LY2603618/gemcitabine arm.
Conclusion
OS was not improved with the addition of LY2603618/
gemcitabine compared with gemcitabine alone. The
safety and PK profiles were comparable between treat-
ment arms. As a result of this finding, LY2603618/gem-
citabine will not be further developed for the treatment
of patients with pancreatic cancer.
Abbreviations
%AUC[tlast-∞]: Percentage of AUC[0-∞] extrapolated; 5-FU: Fluorouracil;
AE: Adverse event; AUC[0-tlast]: Area under the plasma concentration time-
curve from time 0 to the time of the last measurable plasma concentration;
AUC[0-∞]: Area under the plasma concentration time-curve from time 0 to in-
finity; AUC(0–24): Area under the plasma concentration time-curve from time 0
to 24 h; AUC(tlast - ∞): Fraction of AUC(0 - ∞) extrapolated from the time of the
last measurable plasma concentration (tlast) to infinity; CA19-9: Carbohydrate
antigen 19–9; Cav,24: Average plasma concentration over 24 h calculated using
AUC(0–24); CHK1: Checkpoint kinase 1; CI: Confidence intervals; CL: Systemic
clearance; Cmax: Maximum plasma concentration; CR: Complete response;
CTCAE: Common terminology criteria for adverse events; CV%: Percent
coefficient of variation; dFdC 2’: 2’-difluorodeoxycytidine; DNA: Deoxyribonucleic
acid; ECG: Electrocardiogram; ECOG PS: Eastern cooperative oncology group
performance status; FOLFIRINOX: Oxaliplatin, irinotecan, leucovorin, and 5-FU;
ITT: Intent-to-treat; m2: Meters squared; mg: Milligram; MPACT: Metastatic
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pancreatic adenocarcinoma clinical trial; msec: Millisecond; NC: Not calculated;
ORR: Overall response rate; OS: Overall survival; PD: Pharmacodynamic;
PFS: Progression-free survival; PK: Pharmacokinetics; PR: Partial response;
PS: Performance status; QTcF: Fridericia’s heart rate-corrected QT interval;
RA: Intra- and intercycle accumulation ratios; RNAi: Ribonucleic acid interference;
SAE: Serious adverse event; t1/2: Terminal elimination half-life; TEAE: Treatment-
emergent AEs; tmax: Time of maximum observed plasma concentration;
Vss: Volume of distribution at steady-state
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